PAG
CLVS

Private Advisor Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Private Advisor Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,250
Closed -$35K – 3722
2020
Q2 		$35K Buy
+5,250
New +$39.8K ﹤0.01% 2286

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Private Advisor Group's CLVS Position: Q3 2020 in Review

Private Advisor Group sold out of Clovis Oncology, Inc. (CLVS) in Q3 2020, closing a stake of 5,250 shares — an estimated $35K sold.

Private Advisor Group first reported a position in CLVS in Q2 2020 and held it in 1 quarter. The position peaked at $35K in Q2 2020. 169 funds tracked by Wall St. Rank hold CLVS as of Q3 2020.

  • Private Advisor Group reported no remaining Clovis Oncology, Inc. position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 5,250 Clovis Oncology, Inc. shares in Q3 2020, an estimated $35K.
  • Private Advisor Group first reported a position in Clovis Oncology, Inc. in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Clovis Oncology, Inc. position peaked at $35K in Q2 2020.
  • 169 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.